Company news
Urogen Pharma Ltd. (NASDAQ:URGN) news
Urogen Pharma Ltd. news releases on 6ix. Latest, Oct 3, 2023: Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102…
Press releases — page 3
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
October 2, 2023
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
August 9, 2023
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 7, 2023
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 1, 2023
UroGen Announces $120 Million Private Placement of Ordinary Shares
July 26, 2023
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
July 26, 2023
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
July 24, 2023
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
July 9, 2023
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
July 5, 2023
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
June 19, 2023
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 8, 2023
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 10, 2023
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
May 3, 2023
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
April 30, 2023
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
April 29, 2023
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
April 24, 2023
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
March 15, 2023
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
March 8, 2023
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
February 14, 2023
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
January 10, 2023
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
December 18, 2022
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
December 1, 2022
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
November 30, 2022
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
November 20, 2022
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
November 13, 2022
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 9, 2022
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
November 8, 2022
UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
November 2, 2022
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
October 10, 2022
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
September 27, 2022
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
September 11, 2022
UroGen Pharma Announces Upcoming 2022 Conferences
September 6, 2022
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 10, 2022
UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
July 26, 2022
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
May 15, 2022
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
May 12, 2022
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 9, 2022
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
May 2, 2022
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
March 28, 2022
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
March 20, 2022
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven
March 7, 2022
UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022
March 3, 2022
UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
February 28, 2022
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
February 27, 2022
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
February 9, 2022
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
February 2, 2022
UroGen Pharma to Present at Upcoming Conferences
January 4, 2022
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
December 20, 2021
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
November 14, 2021
UroGen Pharma Announces Upcoming 2021 Conferences
November 10, 2021